| pubmed-article:8102222 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8102222 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:8102222 | lifeskim:mentions | umls-concept:C0242531 | lld:lifeskim |
| pubmed-article:8102222 | lifeskim:mentions | umls-concept:C0312418 | lld:lifeskim |
| pubmed-article:8102222 | lifeskim:mentions | umls-concept:C1609982 | lld:lifeskim |
| pubmed-article:8102222 | lifeskim:mentions | umls-concept:C0205341 | lld:lifeskim |
| pubmed-article:8102222 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8102222 | lifeskim:mentions | umls-concept:C0036667 | lld:lifeskim |
| pubmed-article:8102222 | lifeskim:mentions | umls-concept:C2827063 | lld:lifeskim |
| pubmed-article:8102222 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:8102222 | pubmed:dateCreated | 1993-9-8 | lld:pubmed |
| pubmed-article:8102222 | pubmed:abstractText | Cumulative dose-response curves were obtained for vecuronium in 10 patients anaesthetised with thiopentone, enflurane and nitrous oxide using adductor pollicis mechanomyography. Five patients received vecuronium systemically, which was repeated at 100% twitch recovery to obtain initial and repeat curves. Another five patients received 0.3 mg vecuronium into an isolated forearm and at 100% recovery of this arm received vecuronium systemically to obtain simultaneous dose-response curves in both the previously isolated and nonisolated arms. There was no significant difference between the calculated ED50 obtained after initial systemic administration [16.2 (1.7) micrograms.kg-1], after recovery in the previously isolated arm [14.8 (2.0) micrograms.kg-1] and simultaneously in the nonisolated arm [16.1 (2.9) micrograms.kg-1]. The ED50 obtained after repeated systemic administration was significantly reduced [8.2 (2.9) micrograms.kg-1]. These results suggest that the reduction in ED50 at 100% twitch recovery from systemic vecuronium is not due to residual drug at the biophase/receptor but to drug persisting in the plasma. | lld:pubmed |
| pubmed-article:8102222 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8102222 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102222 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8102222 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102222 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102222 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8102222 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:8102222 | pubmed:issn | 0003-2409 | lld:pubmed |
| pubmed-article:8102222 | pubmed:author | pubmed-author:FeldmanS ASA | lld:pubmed |
| pubmed-article:8102222 | pubmed:author | pubmed-author:CampkinN TNT | lld:pubmed |
| pubmed-article:8102222 | pubmed:author | pubmed-author:HoodJ RJR | lld:pubmed |
| pubmed-article:8102222 | pubmed:author | pubmed-author:FauvelN JNJ | lld:pubmed |
| pubmed-article:8102222 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8102222 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:8102222 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8102222 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8102222 | pubmed:pagination | 572-4 | lld:pubmed |
| pubmed-article:8102222 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8102222 | pubmed:meshHeading | pubmed-meshheading:8102222-... | lld:pubmed |
| pubmed-article:8102222 | pubmed:meshHeading | pubmed-meshheading:8102222-... | lld:pubmed |
| pubmed-article:8102222 | pubmed:meshHeading | pubmed-meshheading:8102222-... | lld:pubmed |
| pubmed-article:8102222 | pubmed:meshHeading | pubmed-meshheading:8102222-... | lld:pubmed |
| pubmed-article:8102222 | pubmed:meshHeading | pubmed-meshheading:8102222-... | lld:pubmed |
| pubmed-article:8102222 | pubmed:meshHeading | pubmed-meshheading:8102222-... | lld:pubmed |
| pubmed-article:8102222 | pubmed:meshHeading | pubmed-meshheading:8102222-... | lld:pubmed |
| pubmed-article:8102222 | pubmed:meshHeading | pubmed-meshheading:8102222-... | lld:pubmed |
| pubmed-article:8102222 | pubmed:meshHeading | pubmed-meshheading:8102222-... | lld:pubmed |
| pubmed-article:8102222 | pubmed:meshHeading | pubmed-meshheading:8102222-... | lld:pubmed |
| pubmed-article:8102222 | pubmed:meshHeading | pubmed-meshheading:8102222-... | lld:pubmed |
| pubmed-article:8102222 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8102222 | pubmed:articleTitle | The effect of residual receptor occupancy on sensitivity to repeated vecuronium. | lld:pubmed |
| pubmed-article:8102222 | pubmed:affiliation | Magill Department of Anaesthetics, Chelsea and Westminster Hospital, London. | lld:pubmed |
| pubmed-article:8102222 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8102222 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8102222 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8102222 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:8102222 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
